Grail (GRAL) Competitors $23.62 +0.88 (+3.87%) (As of 12/17/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainSEC FilingsShort InterestTrends GRAL vs. LFST, SGRY, CON, PRVA, ARDT, ADUS, PACS, WGS, NHC, and TDOCShould you be buying Grail stock or one of its competitors? The main competitors of Grail include LifeStance Health Group (LFST), Surgery Partners (SGRY), Concentra Group Holdings Parent (CON), Privia Health Group (PRVA), Ardent Health Partners (ARDT), Addus HomeCare (ADUS), PACS Group (PACS), GeneDx (WGS), National HealthCare (NHC), and Teladoc Health (TDOC). These companies are all part of the "healthcare" industry. Grail vs. LifeStance Health Group Surgery Partners Concentra Group Holdings Parent Privia Health Group Ardent Health Partners Addus HomeCare PACS Group GeneDx National HealthCare Teladoc Health LifeStance Health Group (NASDAQ:LFST) and Grail (NASDAQ:GRAL) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, community ranking, profitability, earnings, institutional ownership, analyst recommendations, valuation, dividends and media sentiment. Does the media favor LFST or GRAL? In the previous week, LifeStance Health Group had 2 more articles in the media than Grail. MarketBeat recorded 8 mentions for LifeStance Health Group and 6 mentions for Grail. LifeStance Health Group's average media sentiment score of 1.02 beat Grail's score of 0.38 indicating that LifeStance Health Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LifeStance Health Group 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Grail 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders & institutionals believe in LFST or GRAL? 85.5% of LifeStance Health Group shares are held by institutional investors. 6.6% of LifeStance Health Group shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Do analysts recommend LFST or GRAL? LifeStance Health Group currently has a consensus price target of $8.70, suggesting a potential upside of 16.31%. Grail has a consensus price target of $16.00, suggesting a potential downside of 32.26%. Given LifeStance Health Group's stronger consensus rating and higher probable upside, equities analysts plainly believe LifeStance Health Group is more favorable than Grail.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LifeStance Health Group 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40Grail 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has higher valuation and earnings, LFST or GRAL? Grail has lower revenue, but higher earnings than LifeStance Health Group. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLifeStance Health Group$1.21B2.37-$186.26M-$0.26-28.77Grail$117.67M6.74N/AN/AN/A Is LFST or GRAL more profitable? Grail has a net margin of 0.00% compared to LifeStance Health Group's net margin of -7.90%. Grail's return on equity of 0.00% beat LifeStance Health Group's return on equity.Company Net Margins Return on Equity Return on Assets LifeStance Health Group-7.90% -6.66% -4.51% Grail N/A N/A N/A Does the MarketBeat Community prefer LFST or GRAL? LifeStance Health Group received 11 more outperform votes than Grail when rated by MarketBeat users. Likewise, 26.19% of users gave LifeStance Health Group an outperform vote while only 0.00% of users gave Grail an outperform vote. CompanyUnderperformOutperformLifeStance Health GroupOutperform Votes1126.19% Underperform Votes3173.81% GrailOutperform VotesNo VotesUnderperform Votes3100.00% SummaryLifeStance Health Group beats Grail on 10 of the 14 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Get Grail News Delivered to You Automatically Sign up to receive the latest news and ratings for GRAL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GRAL vs. The Competition Export to ExcelMetricGrailMedical laboratories IndustryMedical SectorNASDAQ ExchangeMarket Cap$793.66M$2.93B$5.17B$9.32BDividend YieldN/A11.01%4.78%4.06%P/E RatioN/A16.26127.7717.55Price / Sales6.74210.801,261.39139.05Price / CashN/A472.0941.0437.95Price / BookN/A5.224.894.92Net IncomeN/A-$32.86M$119.40M$225.78M7 Day Performance15.19%-2.72%14.54%-1.47%1 Month Performance59.59%10.77%17.43%5.36%1 Year PerformanceN/A17.27%35.31%22.71% Grail Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GRALGrail0.5384 of 5 stars$23.62+3.9%$16.00-32.3%N/A$764.09M$117.67M0.001,360LFSTLifeStance Health Group2.0521 of 5 stars$7.75+8.1%$8.70+12.3%+2.9%$2.97B$1.21B-29.509,325Analyst UpgradeNews CoveragePositive NewsGap UpSGRYSurgery Partners3.564 of 5 stars$22.08+8.4%$36.56+65.6%-35.2%$2.81B$2.74B-42.4213,500Analyst ForecastCONConcentra Group Holdings ParentN/A$21.54+5.1%$28.50+32.3%N/A$2.74B$1.88B0.0011,000Analyst UpgradeGap UpPRVAPrivia Health Group3.2148 of 5 stars$21.56+2.9%$24.80+15.0%-7.8%$2.59B$1.66B209.621,102Analyst ForecastNews CoverageARDTArdent Health PartnersN/A$16.89+1.2%$21.82+29.2%N/A$2.41B$5.41B0.0024,200Analyst ForecastNews CoveragePositive NewsADUSAddus HomeCare4.7566 of 5 stars$131.27+5.0%$133.67+1.8%+40.9%$2.38B$1.06B28.6034,846Analyst ForecastShort Interest ↓PACSPACS Group3.755 of 5 stars$15.17-1.6%$39.88+162.9%N/A$2.31B$3.11B0.0032,433Analyst ForecastWGSGeneDx1.496 of 5 stars$78.19+3.7%$59.33-24.1%+3,159.3%$2.15B$267.23M-24.251,200NHCNational HealthCareN/A$122.67+1.0%N/AN/A$1.89B$1.23B15.2213,123TDOCTeladoc Health2.4882 of 5 stars$10.64+2.1%$12.24+15.0%-50.9%$1.83B$2.60B-1.815,600 Related Companies and Tools Related Companies LifeStance Health Group Alternatives Surgery Partners Alternatives Concentra Group Holdings Parent Alternatives Privia Health Group Alternatives Ardent Health Partners Alternatives Addus HomeCare Alternatives PACS Group Alternatives GeneDx Alternatives National HealthCare Alternatives Teladoc Health Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GRAL) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Grail, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Grail With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GRAL Stock Alerts